Poseida Therapeutics, Inc., a San Diego-based company translating gene engineering technologies into cell therapies, raised $30.5 million in Series B financing.
The round was led by Longitude Capital, with participation from new investors Vivo Capital and the Tavistock Group, and existing investor Malin Corporation plc. In conjunction with the financing, David Hirsch, M.D., Ph.D., managing director at Longitude Capital, has joined Poseida’s Board of Directors.
The company will use the funds to further advance a pipeline of autologous and allogeneic CAR-T immunotherapies, as well as gene therapies, using its suite of gene engineering technologies.
Led by Eric Ostertag, M.D., Ph.D., chief executive officer, Poseida Therapeutics is translating a suite of gene engineering technologies, including the piggyBac™ DNA Modification System, TAL-CLOVER™ and Cas-CLOVER™ site-specific nucleases, and Footprint-Free™ Gene Editing (FFGE) into lifesaving cell therapies.
The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is a CAR-T therapy currently in Phase 1 clinical development for relapsed/refractory multiple myeloma. P-PSMA-101 is a CAR-T therapy in preclinical development for the treatment of prostate cancer. P-BCMA-ALLO1 is an allogeneic “universal donor” CAR-T for multiple myeloma.